Functional imaging-guided radiotherapy and radiolabelled targeted therapies in prostate cancer

Abstract

Positron emission tomography (PET) imaging using PSMA ligand is a promising radiotracer in prostate cancer. Recent trials suggest its potential role in accurate staging of high-risk prostate cancer and detecting metastases and local-regional relapses during biochemical recurrence with 68Ga-PSMA positron emission tomography/computed tomography (PET/CT). However, the data related with its role in radiotherapy are still lacking. Therefore, we summarized our experience with 68Ga-PSMA PET/CT guided hypofractionated stereotactic radiotherapy in patients with oligometastatic disease after biochemical recurrence. Radiolabelled targeted therapies gains popularity in the management metastatic bone disease in prostate cancer. We particularly review the applications of radium-223 chloride in prostate cancer patients in the light of available clinically relevant data.